Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

56.05 +0.73 (+1.32%)
Streaming Delayed Price Updated: 10:08 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
News headline image
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? ↗
The company will be judged by the results of its peers, and it might not compare as well as shareholders hope. 
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles. 
Via The Motley Fool
News headline image
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 ↗
Don't read too much into this year's lackluster performance. Near-term catalysts are firming up. 
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts ↗
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sam Kulkarni outlined the company’s commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected... 
Via MarketBeat
Topics Intellectual Property
News headline image
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine. 
Via The Motley Fool
News headline image
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated. 
Via The Motley Fool
News headline image
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September ↗
Both companies are approaching milestones that could light a fire under their stocks. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗
The company had fallen out of investor favor; its recovery was impressive. 
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗
CRISPR's expanding pipeline could unlock significantly more value by 2031. 
Via The Motley Fool
News headline image
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗
We'll know a little more about the company's prospects by the end of the year. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
Don't bet against Vertex Pharmaceuticals in cystic fibrosis. 
Via The Motley Fool
News headline image
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗
The next six months may be decisive for the biotech. 
Via The Motley Fool
News headline image
3 Stocks With the Most Upside by the End of 2026 ↗
Analysts remain optimistic that the market will view upcoming catalysts in a bullish light. 
Via The Motley Fool
Topics Workforce
News headline image
3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside ↗
These stocks have market caps below $5 billion, but they could be much more valuable in the future. 
Via The Motley Fool
News headline image
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating ↗
This particular position isn't rooted solely in the science you've heard most about from the biopharma company so far. 
Via The Motley Fool
Topics ETFs
News headline image
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗
Beam Therapeutics' growing pipeline could reward patient investors. 
Via The Motley Fool
News headline image
3 Reasons to Buy CRISPR Therapeutics Stock ↗
The company's innovative qualities may pay rich dividends down the road. 
Via The Motley Fool
News headline image
Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis... 
Via MarketBeat
News headline image
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
This new technology could one day significantly expand the market for gene-editing biotechs. 
Via The Motley Fool
News headline image
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗
There's more to young biopharma companies than their numbers, but those numbers are still an important part of each investment thesis. 
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? ↗
One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet. 
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare. 
Via The Motley Fool
News headline image
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles. 
Via The Motley Fool
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Exploring some of the top bargains in a multi-trillion-dollar industry. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗
The opportunity is enormous, but uncertainty remains. 
Via The Motley Fool
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
They have at least one thing in common: An exciting pipeline. 
Via The Motley Fool
Topics ETFs
News headline image
Here's How I'd Invest $10,000 Right Now ↗
My strategy involves focusing on dividends, growth, and also taking on some calculated risk. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.